Travere Therapeutics Quarterly Cash Flow Statement
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Travere Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Travere Therapeutics generated $58.1 million of operating cash flow. That left free cash flow of $58.1 million, a free-cash-flow margin of 34.2% of revenue. Free cash flow was up 1065.4% from the prior year's $5.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Travere Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -34.80M | -37.10M | 2.73M | 25.71M | -12.76M | -41.23M | -60.26M | -54.81M | -70.41M | -136.06M | -90.17M | 150.74M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | -136.36% | — | — | — | — |
| Depreciation & Amortization | 4.23M | 25.21M | 18.14M | 15.79M | 14.02M | 12.80M | 12.09M | 11.24M | 10.35M | 9.88M | 9.49M | 11.47M |
| Stock-Based Compensation | 21.79M | 16.15M | 11.46M | 11.26M | 10.65M | 11.49M | 9.21M | 8.02M | 9.92M | 9.76M | 8.14M | 11.32M |
| Change in Working Capital | -1.60M | -24.22M | 35.10M | -57.03M | -6.98M | -14.15M | 658.00K | -9.12M | 1.91M | -24.42M | -18.10M | -8.30M |
| Operating Cash Flow | 58.07M | -40.37M | 60.68M | 14.32M | 4.98M | -42.19M | -35.72M | -42.51M | -40.24M | -119.00M | -70.47M | -59.13M |
| Capital Expenditures | — | — | — | -140.00K | — | — | — | 0 | -82.00K | 0 | -25.00K | -10.00K |
| Investing Cash Flow | -206.29M | 21.55M | -104.84M | 86.59M | 4.85M | 41.29M | -80.31M | 46.13M | 28.61M | 104.90M | -16.95M | 133.32M |
| Financing Cash Flow | 187.52M | 4.20M | 26.68M | -65.34M | 1.48M | 3.72M | 139.12M | 46.00K | 782.00K | -525.00K | 124.00K | -634.00K |
| Net Change in Cash | 39.37M | -14.67M | -17.89M | 35.78M | 13.26M | 3.36M | 22.13M | 4.12M | -10.96M | -14.93M | -86.07M | 73.37M |
| Free Cash Flow | 58.07M | -40.37M | 60.68M | 14.18M | 4.98M | -42.19M | -35.72M | -42.51M | -40.33M | -119.00M | -70.50M | -59.14M |
This table shows 12 quarterly periods of Travere Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TVTX's reporting calendar. What is a cash flow statement?